Yixian Guo

No. 45 Changchun Street
Beijing, 100053, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 20 publications

Glofitamab-Based Therapy for Relapsed or Refractory CNS Lymphoma: A Multicenter Retrospective Study.

Glofitamab-Based Therapy for Relapsed or Refractory CNS Lymphoma: A Multicenter Retrospective Study.

Journal: Blood cancer discovery

Published: April 10, 2026

Primary sinonasal DLBCL: High prevalence of MCD subtype and CNS risk.

Primary sinonasal DLBCL: High prevalence of MCD subtype and CNS risk.

Journal: Annals of the Academy of Medicine, Singapore

Published: April 01, 2026

Real-world comparison of BTK inhibitors and lenalidomide as first-line maintenance in primary CNS lymphoma: a multi-center retrospective study.

Real-world comparison of BTK inhibitors and lenalidomide as first-line maintenance in primary CNS lymphoma: a multi-center retrospective study.

Journal: Journal of neuro-oncology

Published: January 29, 2026

Initiation timing and treatment duration of eltrombopag added to immunosuppressive therapy in aplastic anemia: a systematic review and meta-analysis.

Initiation timing and treatment duration of eltrombopag added to immunosuppressive therapy in aplastic anemia: a systematic review and meta-analysis.

Journal: Frontiers in oncology

Published: December 12, 2025

Ibrutinib combined with rituximab and high-dose methotrexate in newly diagnosed primary CNS diffuse large B-cell lymphoma: a pilot study with long-term follow-up.

Ibrutinib combined with rituximab and high-dose methotrexate in newly diagnosed primary CNS diffuse large B-cell lymphoma: a pilot study with long-term follow-up.

Journal: Frontiers in oncology

Published: July 19, 2025

Lenalidomide-rituximab with high-dose methotrexate for treatment of patients with newly diagnosed primary cns lymphoma: a promising first-line approach.

Lenalidomide-rituximab with high-dose methotrexate for treatment of patients with newly diagnosed primary cns lymphoma: a promising first-line approach.

Journal: Annals of hematology

Published: July 08, 2025

Meta-analysis evaluating the efficacy and safety of various Bruton tyrosine kinase (BTK) inhibitors for central nervous system lymphoma: Novel covalent BTK inhibitors, except for ibrutinib, also demonstrate good efficacy in the treatment of primary central nervous system lymphoma.

Meta-analysis evaluating the efficacy and safety of various Bruton tyrosine kinase (BTK) inhibitors for central nervous system lymphoma: Novel covalent BTK inhibitors, except for ibrutinib, also demonstrate good efficacy in the treatment of primary central nervous system lymphoma.

Journal: Cancer

Published: May 31, 2025

Serum cytokine pattern for the early identification of hemophagocytic lymphohistiocytosis in diffuse large B-cell lymphoma.

Serum cytokine pattern for the early identification of hemophagocytic lymphohistiocytosis in diffuse large B-cell lymphoma.

Journal: Cytokine

Published: March 06, 2025

Combined autologous hematopoietic stem cell transplantation and CD19 CAR T-cell therapy for relapsed/refractory diffuse large B-cell lymphoma with TP53 mutation: A case report.

Combined autologous hematopoietic stem cell transplantation and CD19 CAR T-cell therapy for relapsed/refractory diffuse large B-cell lymphoma with TP53 mutation: A case report.

Journal: SAGE open medical case reports

Published: September 18, 2024

Variation characteristics and clinical significance of TP53 in patients with myeloid neoplasms.

Variation characteristics and clinical significance of TP53 in patients with myeloid neoplasms.

Journal: Hematology (Amsterdam, Netherlands)

Published: August 14, 2024

Prognostic prediction of systemic immune-inflammation status for patients with colorectal cancer: a novel pyroptosis-related model.

Prognostic prediction of systemic immune-inflammation status for patients with colorectal cancer: a novel pyroptosis-related model.

Journal: World journal of surgical oncology

Published: March 21, 2022

PIM1 genetic alterations associated with distinct molecular profiles, phenotypes and drug responses in diffuse large B-cell lymphoma.

PIM1 genetic alterations associated with distinct molecular profiles, phenotypes and drug responses in diffuse large B-cell lymphoma.

Journal: Clinical and translational medicine

Published: December 21, 2021

Showing 1-12 of 20

Last Updated: 09/26/2026